NASDAQ:VXRTVaxart Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vaxart Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.70 +0.02 (+1.19 %) (As of 04/3/2020 04:00 PM ET) Add Compare Share Today's Range$1.60Now: $1.70▼$1.7050-Day Range$1.04MA: $1.77▼$2.8752-Week Range$0.25Now: $1.70▼$3.50Volume2.15 million shsAverage Volume10.95 million shsMarket Capitalization$120.25 millionP/E RatioN/ADividend YieldN/ABeta-0.54 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Vaxart, Inc., a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingVaxart has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.50, Vaxart has a potential upside of 164.7% from its current price of $1.70.Amount of Analyst CoverageVaxart has only been the subject of 1 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesVaxart has received 257 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVaxart has received 269 “underperform” votes. (Add your “underperform” vote.)Community SentimentVaxart has received 51.14% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Vaxart and other stocks. Vote “Outperform” if you believe VXRT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VXRT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVaxart does not currently pay a dividend.Dividend GrowthVaxart does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaxart insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.30% of the stock of Vaxart is held by insiders.Percentage Held by Institutions56.21% of the stock of Vaxart is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Vaxart are expected to decrease by -100.00% in the coming year, from ($0.02) to $0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxart is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxart is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxart has a P/B Ratio of 6.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.38 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VXRT Previous SymbolNASDAQ:NABI CUSIPN/A CIK72444 Webhttp://www.vaxart.com/ Phone650-550-3500Debt Debt-to-Equity Ratio0.11 Current Ratio1.92 Quick Ratio1.92Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$9.86 million Price / Sales12.20 Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book6.30Profitability EPS (Most Recent Fiscal Year)($0.86) Net Income$-18,650,000.00 Net Margins-189.06% Return on Equity-123.73% Return on Assets-48.65%Miscellaneous Employees34 Outstanding Shares70,734,000Market Cap$120.25 million Next Earnings Date5/14/2020 (Estimated) OptionableNot Optionable Receive VXRT News and Ratings via Email Sign-up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:VXRT Rates by TradingView Vaxart (NASDAQ:VXRT) Frequently Asked Questions How has Vaxart's stock been impacted by COVID-19 (Coronavirus)? Vaxart's stock was trading at $2.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VXRT shares have decreased by 17.9% and is now trading at $1.70. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Vaxart? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vaxart. When is Vaxart's next earnings date? Vaxart is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Vaxart. How were Vaxart's earnings last quarter? Vaxart Inc (NASDAQ:VXRT) released its quarterly earnings data on Thursday, March, 19th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.13). The biotechnology company earned $3.92 million during the quarter, compared to analysts' expectations of $0.60 million. Vaxart had a negative net margin of 189.06% and a negative return on equity of 123.73%. View Vaxart's earnings history. When did Vaxart's stock split? How did Vaxart's stock split work? Vaxart's stock reverse split on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split. What price target have analysts set for VXRT? 2 analysts have issued twelve-month target prices for Vaxart's shares. Their forecasts range from $3.00 to $6.00. On average, they expect Vaxart's stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 164.7% from the stock's current price. View analysts' price targets for Vaxart. Has Vaxart been receiving favorable news coverage? News articles about VXRT stock have trended very negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vaxart earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutVaxart. Who are some of Vaxart's key competitors? Some companies that are related to Vaxart include Atara Biotherapeutics (ATRA), Innate Pharma (IPHA), Avrobio (AVRO), Aptose Biosciences (APTO), MeiraGTx (MGTX), DBV TECHNOLOGIE/S (DBVT), Prevail Therapeutics (PRVL), Agenus (AGEN), Vericel (VCEL), Sorrento Therapeutics (SRNE), Replimune Group (REPL), Cellectis (CLLS), Adaptimmune Therapeutics (ADAP), PDL BioPharma (PDLI) and Voyager Therapeutics (VYGR). What other stocks do shareholders of Vaxart own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Conatus Pharmaceuticals (CNAT), Agile Therapeutics (AGRX), Inovio Pharmaceuticals (INO), Crispr Therapeutics (CRSP), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), Amarin (AMRN), vTv Therapeutics (VTVT) and Anavex Life Sciences (AVXL). Who are Vaxart's key executives? Vaxart's management team includes the following people: Dr. Wouter W. Latour M.B.A., M.D., MBA, Pres, CEO, CFO & Director (Age 61)Dr. Sean N. Tucker, Founder & Chief Scientific Officer (Age 51)Mr. John M. Harland M.B.A., CPA, Consultant (Age 67)Ms. Margaret A. Echerd, VP, Corp. Controller & Principal Accounting Officer (Age 60)Mr. Brant Biehn, Sr. VP of Commercial Operations What is Vaxart's stock symbol? Vaxart trades on the NASDAQ under the ticker symbol "VXRT." How do I buy shares of Vaxart? Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Vaxart's stock price today? One share of VXRT stock can currently be purchased for approximately $1.70. How big of a company is Vaxart? Vaxart has a market capitalization of $120.25 million and generates $9.86 million in revenue each year. The biotechnology company earns $-18,650,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Vaxart employs 34 workers across the globe. View additional information about Vaxart. What is Vaxart's official website? The official website for Vaxart is http://www.vaxart.com/. How can I contact Vaxart? Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected] This page was last updated on 4/4/2020 by MarketBeat.com StaffFeatured Article: Understanding dividend yield and dividend payout ratio
